Do analysts prefer HVO or ARIX?

hVIVO currently has a consensus price target of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, HVO or ARIX?

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 1.02 £17.84M -£0.87 N/A Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A

Is HVO or ARIX more profitable?

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Arix Bioscience 105.64% 6.41% 2.18%

Which has higher valuation and earnings, BTG or HVO?

hVIVO has lower revenue, but higher earnings than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BTG £168.50M 1.01 N/A £5.10 20.78 hVIVO £46.77M 1.02 £17.84M -£0.87 N/A

Is BTG or HVO more profitable?

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets BTG N/A N/A N/A hVIVO -12.48% -14.65% 11.97%

Do analysts recommend CIR or HVO?

hVIVO has a consensus price target of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts recommend HVO or TILS?

hVIVO currently has a consensus target price of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts clearly believe hVIVO is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate VSN or HVO?

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Verseon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verseon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher earnings and valuation, VSN or HVO?

hVIVO has higher revenue and earnings than Verseon. hVIVO is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verseon N/A N/A N/A -£14.30 N/A hVIVO £46.77M 1.02 £17.84M -£0.87 N/A

Is VSN or HVO more profitable?

Verseon has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Verseon's return on equity of 0.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets Verseon N/A N/A N/A hVIVO -12.48% -14.65% 11.97%

hVIVO (HVO) Competitors

GBX 6.90 -0.05 (-0.72%)

As of 12:03 PM Eastern

Compare

HVO vs. ARIX, BTG, CIR, TILS, and VSN

Should you buy hVIVO stock or one of its competitors? MarketBeat compares hVIVO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with hVIVO include Arix Bioscience (ARIX), BTG (BTG), Circassia Group (CIR), Tiziana Life Sciences (TILS), and Verseon (VSN). These companies are all part of the "biotechnology" industry.

How does hVIVO compare to Arix Bioscience?

hVIVO (LON:HVO) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Arix Bioscience	105.64%	6.41%	2.18%

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Arix Bioscience	Neutral

hVIVO has a beta of 1.707, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

hVIVO currently has a consensus price target of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

11.8% of hVIVO shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

hVIVO beats Arix Bioscience on 7 of the 13 factors compared between the two stocks.

How does hVIVO compare to BTG?

BTG (LON:BTG) and hVIVO (LON:HVO) are related small-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

hVIVO has lower revenue, but higher earnings than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£168.50M	1.01	N/A	£5.10	20.78
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

BTG currently has a consensus price target of GBX 160, indicating a potential upside of 50.94%. hVIVO has a consensus price target of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's higher possible upside, analysts clearly believe hVIVO is more favorable than BTG.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

BTG pays an annual dividend of GBX 4.40 per share and has a dividend yield of 4.2%. hVIVO pays an annual dividend of GBX 0.20 per share and has a dividend yield of 2.9%. BTG pays out 86.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. hVIVO pays out -23.0% of its earnings in the form of a dividend.

20.3% of BTG shares are held by institutional investors. Comparatively, 11.8% of hVIVO shares are held by institutional investors. 19.7% of BTG shares are held by company insiders. Comparatively, 4.9% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BTG had 3 more articles in the media than hVIVO. MarketBeat recorded 3 mentions for BTG and 0 mentions for hVIVO. BTG's average media sentiment score of 0.17 beat hVIVO's score of 0.00 indicating that BTG is being referred to more favorably in the media.

Company	Overall Sentiment
BTG	Neutral
hVIVO	Neutral

Summary

BTG beats hVIVO on 12 of the 16 factors compared between the two stocks.

How does hVIVO compare to Circassia Group?

Circassia Group (LON:CIR) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company	Overall Sentiment
Circassia Group	Neutral
hVIVO	Neutral

hVIVO has a consensus price target of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

11.8% of hVIVO shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Circassia Group has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Circassia Group's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

hVIVO has higher revenue and earnings than Circassia Group. hVIVO is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A

Summary

hVIVO beats Circassia Group on 7 of the 11 factors compared between the two stocks.

How does hVIVO compare to Tiziana Life Sciences?

hVIVO (LON:HVO) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

11.8% of hVIVO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Tiziana Life Sciences' return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Tiziana Life Sciences	N/A	N/A	N/A

hVIVO has higher revenue and earnings than Tiziana Life Sciences. hVIVO is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

In the previous week, Tiziana Life Sciences had 7 more articles in the media than hVIVO. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 0 mentions for hVIVO. Tiziana Life Sciences' average media sentiment score of 0.82 beat hVIVO's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
hVIVO	Neutral
Tiziana Life Sciences	Positive

hVIVO currently has a consensus target price of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts clearly believe hVIVO is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tiziana Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

hVIVO beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.

How does hVIVO compare to Verseon?

Verseon (LON:VSN) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

hVIVO has higher revenue and earnings than Verseon. hVIVO is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verseon	N/A	N/A	N/A	-£14.30	N/A
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 117.39%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Verseon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verseon	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

11.8% of hVIVO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Verseon has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Verseon's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verseon	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

In the previous week, Verseon's average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company	Overall Sentiment
Verseon	Neutral
hVIVO	Neutral

Summary

hVIVO beats Verseon on 8 of the 11 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HVO vs. The Competition

Export

Metric	hVIVO	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£47.50M	£3.61B	£6.93B	£2.87B
Dividend Yield	2.68%	3.77%	2.60%	6.13%
P/E Ratio	-7.93	7.68	281.16	369.49
Price / Sales	1.02	1,223.93	575.77	83,955.53
Price / Cash	4.94	103.01	71.79	27.89
Price / Book	1.24	17.03	12.86	7.07
Net Income	£17.84M	-£12.50M	£3.49B	£5.89B
7 Day Performance	-10.97%	2.90%	2.63%	1.18%
1 Month Performance	-2.82%	-4.49%	-2.64%	0.90%
1 Year Performance	-31.00%	54.14%	76.00%	75.31%

hVIVO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HVO hVIVO	N/A	GBX 6.90 -0.7%	GBX 15 +117.4%	-30.0%	£47.50M	£46.77M	N/A	N/A
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
BTG BTG	4.021 of 5 stars	GBX 106.50 -0.9%	GBX 160 +50.2%	N/A	£171.62M	£159.40M	17.75	4,690
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HVO) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

hVIVO (HVO) Competitors

HVO vs. ARIX, BTG, CIR, TILS, and VSN

How does hVIVO compare to Arix Bioscience?

Summary

How does hVIVO compare to BTG?

Summary

How does hVIVO compare to Circassia Group?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Summary

How does hVIVO compare to Verseon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

hVIVO (HVO) Competitors

HVO vs. ARIX, BTG, CIR, TILS, and VSN

How does hVIVO compare to Arix Bioscience?

Which has stronger earnings and valuation, HVO or ARIX?

Is HVO or ARIX more profitable?

Does the media favor HVO or ARIX?

Which has more risk & volatility, HVO or ARIX?

Do analysts prefer HVO or ARIX?

Do insiders & institutionals hold more shares of HVO or ARIX?

Summary

How does hVIVO compare to BTG?

Which has higher valuation and earnings, BTG or HVO?

Is BTG or HVO more profitable?

Do analysts prefer BTG or HVO?

Is BTG or HVO a better dividend stock?

Do insiders and institutionals have more ownership in BTG or HVO?

Does the media refer more to BTG or HVO?

Summary

How does hVIVO compare to Circassia Group?

Does the media favor CIR or HVO?

Do analysts recommend CIR or HVO?

Do insiders & institutionals have more ownership in CIR or HVO?

Is CIR or HVO more profitable?

Which has preferable valuation & earnings, CIR or HVO?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Do institutionals & insiders have more ownership in HVO or TILS?

Is HVO or TILS more profitable?

Which has preferable earnings & valuation, HVO or TILS?

Does the media favor HVO or TILS?

Do analysts recommend HVO or TILS?

Summary

How does hVIVO compare to Verseon?

Which has higher earnings and valuation, VSN or HVO?

Do analysts rate VSN or HVO?

Do institutionals and insiders believe in VSN or HVO?

Is VSN or HVO more profitable?

Does the media refer more to VSN or HVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools